Welcome to RadioGel®

Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors. The Y-90 RadioGel™/Hydrogel mixture is injected directly and uniformly into tumors.

 IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy. To read the full press releases click here.  Read the Press Release

RadioGel™ is currently not approved for human use. 

Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. 

We are a team dedicated to developing a safer, less invasive cancer treatment for humans and animals worldwide.

Sign up to have the latest press releases sent directly to your inbox.

RadioGel is a division of Vivos Inc.